Speech
Measures articulation, phonation, and speech rate to quantify speech and language performance
63
Syllables Detected
5.8 syll/s
DDK rate
16%
DDK Variability
MindPlus
MindPlus is an AI-powered digital wellness platform for monitoring neurodegenerative brain diseases in adults. It integrates and analyzes voice, facial movement, gait, gaze, hearing, and other indicators to assess physical and cognitive function in everyday life and support the early identification of neurodegenerative signals.
Integrated Data Analysis
Assessment and Early Diagnosis
Treatment Progress Monitoring
Key features
Making subtle neurological and cognitive changes visible with multimodal AI. MindPlus is Korea’s first AI-powered digital wellness platform for collecting and analyzing multimodal neurobehavioral data.
Early Monitoring of Neurodegenerative Changes
AI quantifies subtle changes in speech, gaze, and gait, enabling early recognition of shifts in cognitive and neurological function.
Safe and Rapid Assessment
A non-invasive, non-contact method ensures user safety, with the full assessment completed in 15–20 minutes.
Cost-Efficient SaaS Model
A SaaS-based solution that operates without dedicated equipment, reducing costs and lowering barriers to on-site adoption.
Multimodal
Analysis
Analysis
AI models integrate and analyze voice, facial movement, gait, gaze, and hearing data to provide a multidimensional view of a patient’s condition and support early assessment and treatment-progress monitoring.
Face
Analyzes facial movement and bilateral symmetry frame by frame to quantify facial motor function
478
Facial Landmarks
97%
Facial Symmetry
12%
Mouth Opening Ratio
Gait
Measures gait speed, step length, and left–right asymmetry from video to monitor mobility and fall risk
0.63 m/s
Gait Speed
75 cm
Step Length
60/100
Gait Score
Gaze Tracking
Quantifies reading scan paths, regressions, and eye–voice coordination to assess reading efficiency and lexical retrieval
46 s
Reading Time
219 ms
Mean Fixation Duration
9
Regressions
Hearing
Measures frequency-specific pure-tone and speech-recognition thresholds to screen for hearing loss
28.3 dB HL
6-Frequency PTA
80 dB HL
4 kHz Threshold
Mild Loss
Classification
Integrated Report
Integrates all five modalities to visualize norm-referenced performance and session-to-session change
80/100
Overall Score
5
Assessment Modalities
Within Expected Range
Overall Rating
Applications
Target Conditions
Major neurological disorders including Alzheimer's disease (AD), Parkinson's disease (PD), and idiopathic normal pressure hydrocephalus (iNPH)
Intended Use Settings
University hospitals, specialized hospitals and clinics, dementia care centers, public health institutions, and long-term care facilities
Clinical
Adoption
